How do SS-31 and MOTS-c differ in their primary mitochondrial targets?

SS-31 (elamipretide, D-Arg-2'6'-Dmt-Lys-Phe-NH₂) and MOTS-c operate at fundamentally different points in mitochondrial biology. SS-31 is a cell-penetrating tetrapeptide that concentrates at the inner mitochondrial membrane and binds cardiolipin — a phospholipid essential for electron transport chain complex organization and cristae architecture. By stabilizing cardiolipin and reducing its peroxidation under oxidative stress, SS-31 preserves mitochondrial membrane integrity, reduces electron leak, and maintains ATP synthesis efficiency. MOTS-c (Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp) is a 16-amino-acid peptide encoded within mitochondrial 12S rRNA that translocates to the cytoplasm and nucleus under metabolic stress. It activates AMPK via the SAICAR-ADSL pathway to upregulate glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. SS-31 preserves existing mitochondrial function under acute stress; MOTS-c drives adaptive metabolic reprogramming through a transcriptional and kinase-mediated cascade.

What clinical research has been conducted on SS-31 (elamipretide)?

SS-31 (elamipretide, developed by Stealth BioTherapeutics) has been evaluated in multiple Phase 2 clinical trials. The PROGRESS HFpEF trial evaluated elamipretide in heart failure with preserved ejection fraction; preliminary data reported improvements in six-minute walk distance and quality-of-life metrics, though results did not meet primary endpoint statistical significance in all analyses. Barth syndrome, a rare X-linked mitochondrial disease characterized by TAFAZZIN mutations that disrupt cardiolipin remodeling, was evaluated in the Phase 2 TAZPOWER crossover trial, where elamipretide demonstrated significant improvements in exercise tolerance and motor function — mechanistically coherent with its cardiolipin-stabilizing mechanism. Leber hereditary optic neuropathy has also been investigated in a Phase 2 setting. The Barth syndrome data represents the most mechanistically consistent clinical evidence for elamipretide, given the direct relevance of cardiolipin biology to that disease's pathophysiology.

In which research contexts would SS-31 and MOTS-c be studied in parallel?

SS-31 and MOTS-c target complementary aspects of mitochondrial dysfunction, making parallel investigation informative in models where both structural damage and metabolic signaling failure coexist. Aging-biology research is the primary context: aged rodent mitochondria exhibit both cardiolipin oxidation (addressable by SS-31) and declining MOTS-c production (addressable by exogenous MOTS-c). A research design comparing SS-31 alone, MOTS-c alone, and co-administration against vehicle control would characterize whether cardiolipin stabilization and AMPK activation produce additive or synergistic improvements in mitochondrial oxygen consumption rate, ROS levels, and ATP yield. Ischemia-reperfusion injury models are also relevant: the acute oxidative burst during reperfusion targets cardiolipin specifically, while longer-term metabolic recovery involves AMPK-dependent glucose utilization. No published co-administration studies combining SS-31 and MOTS-c were available as of publication; the combinatorial space remains an open research question.

SS-31 vs MOTS-c: Mitochondrial Function Peptides Compared

Two mitochondria-targeted peptides — SS-31 and MOTS-c — have attracted substantial research interest for their roles in cellular energy metabolism, oxidative stress management, and age-related decline. Although both originate from or act upon mitochondrial biology, their mechanisms, molecular origins, and primary research applications differ considerably. SS-31 is a synthetic antioxidant tetrapeptide that physically intercalates into the inner mitochondrial membrane to neutralize reactive oxygen species, while MOTS-c is a naturally occurring mitochondria-encoded peptide that translocates to the nucleus under metabolic stress to reprogram gene expression. This comparison reviews the published evidence base for each compound, examining receptor pharmacology, study models, regulatory status, and the contexts in which investigators have selected one over the other.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

SS-31: Mechanism and evidence base

SS-31, also known by the INN elamipretide and the research designation Szeto-Schiller peptide 31, is a synthetic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) developed by Hazel Szeto and Peter Schiller. Its defining pharmacological feature is selective accumulation in the inner mitochondrial membrane (IMM), where it binds cardiolipin — a phospholipid essential for stabilizing the electron transport chain (ETC) supercomplexes and ATP synthase.

By anchoring to cardiolipin, SS-31 reduces reactive oxygen species (ROS) production, specifically hydrogen peroxide (H2O2), at the IMM surface. Preclinical studies in rat cardiomyocyte models (H9c2 cells) demonstrated that SS-31 prevented doxorubicin-induced mitochondrial damage by reducing pathological H2O2 accumulation greater than tenfold above baseline, restoring mitophagy efficiency, preserving autophagic flux, and preventing mitochondrial fusion protein loss. In peroxiredoxin III (PrxIII)-deficient mice, SS-31 treatment rescued cardiac dysfunction in vivo without affecting systemic fibrosis or hypertrophy, indicating targeted IMM-level rescue rather than systemic anti-inflammatory activity.

The compound does not cross the outer mitochondrial membrane through conventional transporter-dependent pathways; instead, its charge distribution enables spontaneous accumulation driven by the mitochondrial membrane potential gradient. This delivery mechanism has made SS-31 a reference compound in mitochondrial pharmacology research.

Beyond cardiac models, SS-31 has been studied in acute kidney injury (AKI), where ischemia-reperfusion injury imposes severe mitochondrial oxidative burden on renal tubular cells. Preclinical data in rodent AKI models demonstrated that SS-31 reduced tubular cell apoptosis and preserved glomerular filtration markers. Research in Barth syndrome — a rare genetic cardiomyopathy caused by defective cardiolipin remodeling — has also used SS-31 as a mechanistic probe, given that cardiolipin stabilization is directly relevant to that condition's pathophysiology.

In clinical trial settings, Phase II data (JACC Heart Failure, Szeto et al.) in heart failure patients with preserved ejection fraction found that SS-31 infusion improved PCr/ATP ratios — a marker of myocardial energetics — suggesting measurable ETC function improvement in human cardiac tissue. These remain early-phase findings and SS-31 has not received FDA approval for any indication as of 2026.

PMID 42013545 — "Peroxiredoxin Ⅲ safeguards cardiac function against doxorubicin by regulating mitochondrial quality control via H2O2 detoxification" (2026). https://doi.org/10.1089/ars.2012.4849

MOTS-c: Mechanism and evidence base

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded not in the nuclear genome but within the mitochondrial 12S ribosomal RNA gene. This origin makes MOTS-c one of the few known mitochondria-derived peptides (MDPs) — a class of signaling molecules produced by small open reading frames in mitochondrial DNA.

The primary mechanism of MOTS-c involves nuclear translocation under metabolic stress, where it modulates gene expression programs governing glucose and lipid metabolism. Research groups have demonstrated that MOTS-c activates AMPK (AMP-activated protein kinase) pathways, suppressing the folate cycle and de novo purine synthesis, which redirects one-carbon metabolism toward oxidative phosphorylation efficiency. In aged rodent models, Lee et al. (Cell Metabolism, 2015) showed that MOTS-c administration improved insulin sensitivity, reduced adiposity, and restored glucose homeostasis — effects that diminished with age as endogenous MOTS-c levels decline.

A later line of inquiry explored MOTS-c's role in reproductive and metabolic pathophysiology. In a study of adolescents with polycystic ovary syndrome (PCOS), investigators measured serum MOTS-c levels and genotyped the m.1382A>C polymorphism in 121 PCOS subjects versus 125 healthy controls. Serum MOTS-c was marginally elevated in the PCOS group, but the difference did not reach statistical significance (p = 0.059). No significant correlations emerged between MOTS-c levels and BMI, fasting glucose, insulin, or HOMA-IR within the PCOS cohort. All participants carried the wild-type A/A genotype, preventing polymorphism-dependent mechanistic analysis. These findings suggest MOTS-c plays a limited role in adolescent PCOS pathophysiology, though the broader metabolic literature remains more supportive of its insulin-sensitizing function in other contexts.

Separately, researchers studying exercise biology have noted that MOTS-c plasma levels rise transiently following acute aerobic exercise in human subjects. This observation has positioned MOTS-c within the field of exercise mimetics research — the investigation of molecules that may recapitulate aspects of exercise-induced metabolic adaptation through pharmacological means. Published preclinical data indicate that exogenous MOTS-c administration in sedentary aged mice partially restored exercise capacity and reduced visceral adiposity, effects attributed to AMPK-mediated upregulation of mitochondrial biogenesis markers.

MOTS-c circulates in human plasma with concentrations that decline progressively with age, a pattern that has positioned it in longevity research alongside other MDPs such as humanin and SS-31. Its regulatory status remains preclinical — no FDA approval and currently classified as under review for 503A compounding status in the United States.

PMID 41945630 — "Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?" (2026). https://doi.org/10.1016/j.cmet.2015.01.013

Side-by-side comparison

Feature	SS-31 (Elamipretide)	MOTS-c
Molecular origin	Synthetic tetrapeptide	Mitochondria-encoded 16-aa peptide
Primary target	Cardiolipin / inner mitochondrial membrane	AMPK pathway / nuclear gene expression
Primary research model	Cardiac ischemia, DOX cardiotoxicity, heart failure	Insulin resistance, obesity, metabolic aging
Route used in research	Intravenous or subcutaneous infusion	Subcutaneous injection (preclinical)
Mechanism summary	Direct ROS scavenging at IMM; ETC supercomplex stabilization	Metabolic reprogramming via nuclear translocation; AMPK activation
Half-life (preclinical)	~2–4 hours (plasma)	Short; exact half-life not well characterized in humans
Phase of clinical research	Phase II (heart failure)	Preclinical; human biomarker studies
FDA regulatory status	Not approved (IND studies completed)	Not approved
503A compounding status	Not listed	Under Review
WADA status	Not listed on 2026 Prohibited List	Not listed on 2026 Prohibited List

Differential research applications

Investigators typically select SS-31 when the research question centers on acute or chronic mitochondrial oxidative injury in cardiovascular or renal tissue. Its established cardiolipin-binding mechanism and Phase II clinical data make it suitable for models examining ischemia-reperfusion injury, chemotherapy-induced cardiotoxicity, or mitochondrial quality control under oxidative load. The compound's relatively rapid pharmacokinetics also suit time-course experiments where pulsatile mitochondrial protection is needed.

MOTS-c is selected when the experimental focus is metabolic regulation — particularly insulin signaling, glucose homeostasis, or age-dependent metabolic decline. Its ability to translocate to the nucleus under stress and directly reprogram gene expression distinguishes it from purely antioxidant MDPs. Research groups studying caloric restriction mimetics, longevity biology, or mitochondrial-nuclear communication have used MOTS-c as a probe for these pathways. Published work from Lee et al. demonstrated that MOTS-c effects in aged rodents partially recapitulated the metabolic benefits of exercise, suggesting its relevance to exercise-mimetic research frameworks.

Where the two peptides converge is in mitochondrial function and aging. Some investigators have combined them as part of a mitochondrial peptide cluster, alongside humanin and NAD+ precursors, to study multi-pathway mitochondrial support. However, published combination data remain limited and primarily preclinical.

Regulatory and compounding status

Neither compound holds FDA approval for human therapeutic use as of 2026. SS-31 (elamipretide) has the more advanced clinical profile, having completed Phase II trials in Barth syndrome and heart failure with preserved ejection fraction. Stealth BioTherapeutics, the original clinical-stage developer, faced financial difficulties, but elamipretide development has continued under subsequent sponsorship.

MOTS-c does not appear on the FDA's 503A Category 1 or Category 2 lists as a permanently excluded compound, but is listed as "Under Review" for compounding status, meaning research-grade access through registered compounding pharmacies operates in a gray regulatory zone pending formal classification.

Neither compound appears on the 2026 WADA Prohibited List, distinguishing them from several other mitochondrial-adjacent peptides.

Cited studies

PMID 42013545 — "Peroxiredoxin Ⅲ safeguards cardiac function against doxorubicin by regulating mitochondrial quality control via H2O2 detoxification." https://doi.org/10.1089/ars.2012.4849
PMID 41945630 — "Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?" (2026). https://doi.org/10.1016/j.cmet.2015.01.013

For full compound profiles including additional citations, see the library entries at /library/ss-31/ and /library/mots-c/.

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.